Etanidazole (BioDeep_00000178831)
human metabolite blood metabolite
代谢物信息卡片
N-(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)ethanimidic acid
化学式: C7H10N4O4 (214.070202)
中文名称: 依他硝唑
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CN(C(=N1)[N+](=O)[O-])CC(=O)NCCO
InChI: InChI=1S/C7H10N4O4/c12-4-2-8-6(13)5-10-3-1-9-7(10)11(14)15/h1,3,12H,2,4-5H2,(H,8,13)
描述信息
C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent
D011838 - Radiation-Sensitizing Agents
D000970 - Antineoplastic Agents
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:75473
- PubChem: 3276
- HMDB: HMDB0251988
- DrugBank: DB12736
- ChEMBL: CHEMBL47405
- Wikipedia: Etanidazole
- MeSH: Etanidazole
- chemspider: 3161
- CAS: 22668-01-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Lilie L Lin, Antti Silvoniemi, James B Stubbs, Ramesh Rengan, Sami Suilamo, Olof Solin, Chaitanya Divgi, Olli Eskola, Jonathan M Sorger, Michael G Stabin, Alexander Kachur, Stephen M Hahn, Tove J Grönroos, Sarita Forsback, Sydney M Evans, Cameron J Koch, Heikki Minn. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Cancer biotherapy & radiopharmaceuticals.
2012 Sep; 27(7):412-9. doi:
10.1089/cbr.2011.1130. [PMID: 22897720] - Olli Eskola, Tove J Grönroos, Sarita Forsback, Johanna Tuomela, Gaber Komar, Jörgen Bergman, Pirkko Härkönen, Merja Haaparanta, Heikki Minn, Olof Solin. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Molecular imaging and biology.
2012 Apr; 14(2):205-12. doi:
10.1007/s11307-011-0484-4. [PMID: 21448777] - Johanna M U Silvola, Antti Saraste, Sarita Forsback, V Jukka O Laine, Pekka Saukko, Suvi E Heinonen, Seppo Ylä-Herttuala, Anne Roivainen, Juhani Knuuti. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Arteriosclerosis, thrombosis, and vascular biology.
2011 May; 31(5):1011-5. doi:
10.1161/atvbaha.110.221440. [PMID: 21372297] - M Soltani, P Chen. Numerical modeling of fluid flow in solid tumors.
PloS one.
2011; 6(6):e20344. doi:
10.1371/journal.pone.0020344. [PMID: 21673952] - Cameron J Koch, Joshua S Scheuermann, Chaitanya Divgi, Kevin D Judy, Alexander V Kachur, Richard Freifelder, Janet S Reddin, Joel Karp, James B Stubbs, Stephen M Hahn, Jason Driesbaugh, Deborah Smith, Susan Prendergast, Sydney M Evans. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
European journal of nuclear medicine and molecular imaging.
2010 Nov; 37(11):2048-59. doi:
10.1007/s00259-010-1517-y. [PMID: 20585774] - Mingda Han, Patrizia Trotta, Carl Coleman, Kersti K Linask. MCT-4, A511/Basigin and EF5 expression patterns during early chick cardiomyogenesis indicate cardiac cell differentiation occurs in a hypoxic environment.
Developmental dynamics : an official publication of the American Association of Anatomists.
2006 Jan; 235(1):124-31. doi:
10.1002/dvdy.20531. [PMID: 16110503] - Maria Jose Morilla, Jorge Montanari, Fernanda Frank, Emilio Malchiodi, Ricardo Corral, Patricia Petray, Eder Lilia Romero. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity.
Journal of controlled release : official journal of the Controlled Release Society.
2005 Apr; 103(3):599-607. doi:
10.1016/j.jconrel.2004.12.012. [PMID: 15820407] - H Barthel, H Wilson, D R Collingridge, G Brown, S Osman, S K Luthra, F Brady, P Workman, P M Price, E O Aboagye. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.
British journal of cancer.
2004 Jun; 90(11):2232-42. doi:
10.1038/sj.bjc.6601862. [PMID: 15150578] - L Nadal-Desbarats, H Poptani, P Oprysko, W T Jenkins, T M Busch, D S Nelson, J D Glickson, C J Koch, S M Evans. Effects of hyperglycemia on oxygenation, radiosensitivity and bioenergetic status of subcutaneous RIF-1 tumors.
International journal of oncology.
2002 Jul; 21(1):103-10. doi:
10.3892/ijo.21.1.103. [PMID: 12063556] - L S Ziemer, C J Koch, A Maity, D P Magarelli, A M Horan, S M Evans. Hypoxia and VEGF mRNA expression in human tumors.
Neoplasia (New York, N.Y.).
2001 Nov; 3(6):500-8. doi:
10.1038/sj.neo.7900195. [PMID: 11774032] - C J Koch, S M Hahn, K Rockwell, J M Covey, W G McKenna, S M Evans. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Cancer chemotherapy and pharmacology.
2001 Sep; 48(3):177-87. doi:
10.1007/s002800100324. [PMID: 11592338] - W R Dolbier, A R Li, C J Koch, C Y Shiue, A V Kachur. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
2001 Jan; 54(1):73-80. doi:
10.1016/s0969-8043(00)00102-0. [PMID: 11144255] - J S Rasey, P D Hofstrand, L K Chin, T J Tewson. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
1999 Jun; 40(6):1072-9. doi:
. [PMID: 10452326] - A P Meeson, M Argilla, K Ko, L Witte, R A Lang. VEGF deprivation-induced apoptosis is a component of programmed capillary regression.
Development (Cambridge, England).
1999 Apr; 126(7):1407-15. doi:
10.1242/dev.126.7.1407. [PMID: 10068634] - A D Elias, C Wheeler, L J Ayash, G Schwartz, J Ibrahim, L Mills, M McCauley, N Coleman, D Warren, L Schnipper, K H Antman, B A Teicher, E Frei. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1998 Jun; 4(6):1443-9. doi:
NULL. [PMID: 9626461] - E L Chang, J S Loeffler, N E Riese, P Y Wen, E Alexander, P M Black, C N Coleman. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
International journal of radiation oncology, biology, physics.
1998 Jan; 40(1):65-70. doi:
10.1016/s0360-3016(97)00486-0. [PMID: 9422559] - N E Riese, L Buswell, L Noll, T F Pajak, J Stetz, D J Lee, C N Coleman. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
International journal of radiation oncology, biology, physics.
1997 Nov; 39(4):855-8. doi:
10.1016/s0360-3016(97)00454-9. [PMID: 9369134] - C A Lawton, C N Coleman, J W Buzydlowski, J D Forman, V A Marcial, J D DelRowe, M Rotman. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
International journal of radiation oncology, biology, physics.
1996 Oct; 36(3):673-80. doi:
10.1016/s0360-3016(96)00336-7. [PMID: 8948352] - B A Bornstein, T S Herman, J L Hansen, L Buswell, P S Zouranjian, S M Fraser, B A Teicher, G K Svensson, C N Coleman. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
1995 Jul; 11(4):489-99. doi:
10.3109/02656739509022484. [PMID: 7594803] - K K Chan, P S Hong, K Tutsch, D L Trump. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Cancer research.
1994 Dec; 54(24):6421-9. doi:
. [PMID: 7987837] - L N Shulman, L Buswell, H Goodman, M Muto, R Berkowitz, B Teicher, T Kusumoto, S J Hurwitz, L A Kalish, C N Coleman. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer.
International journal of radiation oncology, biology, physics.
1994 Jun; 29(3):545-8. doi:
10.1016/0360-3016(94)90453-7. [PMID: 8005814] - L N Shulman, L Buswell, L A Kalish, C N Coleman. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.
International journal of radiation oncology, biology, physics.
1994 Jun; 29(3):541-3. doi:
10.1016/0360-3016(94)90452-9. [PMID: 8005813] - N E Riese, J S Loeffler, P Wen, E Alexander, P M Black, C N Coleman. A phase I study of etanidazole and radiotherapy in malignant glioma.
International journal of radiation oncology, biology, physics.
1994 Jun; 29(3):617-20. doi:
10.1016/0360-3016(94)90468-5. [PMID: 8005825] - F E Halberg, D Cosmatis, L L Gunderson, R D Noyes, G R Hanks, L Buswell, D M Nagorney, C N Coleman. RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies.
International journal of radiation oncology, biology, physics.
1994 Jan; 28(1):201-6. doi:
10.1016/0360-3016(94)90158-9. [PMID: 8270442] - P J O'Dwyer, L Panting, F P LaCreta, M L Clapper. SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.
Biochemical pharmacology.
1993 Oct; 46(7):1251-6. doi:
10.1016/0006-2952(93)90475-c. [PMID: 8216377] - P J O'Dwyer, F P LaCreta, J Walczak, T Cox, S Litwin, J P Hoffman, M Zimny, R L Comis. Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.
British journal of cancer.
1993 Oct; 68(4):756-66. doi:
10.1038/bjc.1993.424. [PMID: 8398704] - B A Teicher, T S Herman, K Menon, T T Korbut. Whole-body hyperthermia as an adjuvant to treatment with platinum complexes with or without etanidazole in mice bearing the Lewis lung carcinoma or the FSaLL fibrosarcoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
1992 Nov; 8(6):783-94. doi:
10.3109/02656739209005026. [PMID: 1479204] - R Santus, C C Stobbe, M S McPhee, J D Chapman. Protection against light-activated photofrin II killing of tumor cells by nitroimidazoles.
Radiation research.
1992 Apr; 130(1):31-7. doi:
10.2307/3578476. [PMID: 1532856] - C Murayama, A Suzuki, C Sato, Y Tanabe, Y Miyata, T Shoji, T Suzuki, M Sakaguchi, T Mori. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
International journal of radiation oncology, biology, physics.
1992; 22(3):557-60. doi:
10.1016/0360-3016(92)90875-i. [PMID: 1531214] - L Busutti, A Breccia, E Ferri, F Falcone, F Bertoni. Kinetic uptake of etanidazole in lung carcinoma and normal tissue in vivo.
International journal of radiation oncology, biology, physics.
1992; 22(3):585-8. doi:
10.1016/0360-3016(92)90882-i. [PMID: 1531219] - C N Coleman, L Buswell, L Noll, N Riese, M A Rose. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
International journal of radiation oncology, biology, physics.
1992; 22(3):565-8. doi:
10.1016/0360-3016(92)90877-k. [PMID: 1310497] - S J Hurwitz, C N Coleman, N Riese, J S Loeffler, E Alexander, L Buswell, T Y Neben, L Shargel, R A Kramer. Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.
International journal of radiation oncology, biology, physics.
1992; 22(3):573-6. doi:
10.1016/0360-3016(92)90879-m. [PMID: 1531216] - B A Teicher, M R Pfeffer, E Alvarez Sotomayor, T S Herman. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
1991 Sep; 7(5):773-84. doi:
10.3109/02656739109056446. [PMID: 1834752] - S M Evans, F LaCreta, S Helfand, T VanWinkle, W J Curran, D Q Brown, G Hanks. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma.
International journal of radiation oncology, biology, physics.
1991 Apr; 20(4):703-8. doi:
10.1016/0360-3016(91)90012-s. [PMID: 1825993] - T S Maughan, H F Newman, N M Bleehen, R Ward, P Workman. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
International journal of radiation oncology, biology, physics.
1990 May; 18(5):1151-6. doi:
10.1016/0360-3016(90)90452-p. [PMID: 2140825] - K H Wong, C A Wallen, K T Wheeler. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
International journal of radiation oncology, biology, physics.
1990 May; 18(5):1043-50. doi:
10.1016/0360-3016(90)90439-q. [PMID: 2140824] - C N Coleman, T H Wasserman, R C Urtasun, J Halsey, L Noll, S Hancock, T L Phillips. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
International journal of radiation oncology, biology, physics.
1990 Feb; 18(2):389-93. doi:
10.1016/0360-3016(90)90105-s. [PMID: 2154420] - A F Shields, F R Applebaum, T Graham, H J Deeg, J Allalunis-Turner, J D Chapman, R Storb. Bone marrow toxicity of total-body irradiation combined with radiosensitizers.
Radiation research.
1989 Nov; 120(2):364-9. doi:
10.2307/3577721. [PMID: 2533359] - C Murayama, A Suzuki, T Suzuki, Y Miyata, M Sakaguchi, Y Tanabe, N Tanaka, T Mori. Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170).
International journal of radiation oncology, biology, physics.
1989 Sep; 17(3):575-81. doi:
10.1016/0360-3016(89)90109-0. [PMID: 2528527] - P Workman, R Ward, T S Maughan, H F Newman, N M Bleehen. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
International journal of radiation oncology, biology, physics.
1989 Jul; 17(1):177-81. doi:
10.1016/0360-3016(89)90386-6. [PMID: 2526107] - F Lespinasse, C Thomas, M Bonnay, E P Malaise, M Guichard. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508.
International journal of radiation oncology, biology, physics.
1989 Apr; 16(4):1105-9. doi:
10.1016/0360-3016(89)90927-9. [PMID: 2522920] - P Workman. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination.
International journal of radiation oncology, biology, physics.
1989 Apr; 16(4):1011-4. doi:
10.1016/0360-3016(89)90905-x. [PMID: 2522916] - T Mori. [Radiosensitizer: hypoxic cell radiosensitizer].
Gan to kagaku ryoho. Cancer & chemotherapy.
1989 Apr; 16(4 Pt 2-2):1399-404. doi:
NULL. [PMID: 2525001] - C N Coleman, L Noll, A E Howes, J R Harris, J Zakar, R A Kramer. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
International journal of radiation oncology, biology, physics.
1989 Apr; 16(4):1085-7. doi:
10.1016/0360-3016(89)90922-x. [PMID: 2522919] - H K Awwad, S el Badawy, H abd el Baki, M Zaghloul, A el Moneim Osman, H Akoush, K Fairchild. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
International journal of radiation oncology, biology, physics.
1989 Apr; 16(4):1083-4. doi:
10.1016/0360-3016(89)90921-8. [PMID: 2522918] - H F Newman, R Ward, P Workman, N M Bleehen. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
International journal of radiation oncology, biology, physics.
1988 Nov; 15(5):1073-83. doi:
10.1016/0360-3016(88)90187-3. [PMID: 2972667] - H F Newman, N M Bleehen, R Ward, P Workman. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
International journal of radiation oncology, biology, physics.
1988 Sep; 15(3):677-84. doi:
10.1016/0360-3016(88)90311-2. [PMID: 2843488] - C N Coleman, J Halsey, R S Cox, V K Hirst, T Blaschke, A E Howes, T H Wasserman, R C Urtasun, T Pajak, S Hancock. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Cancer research.
1987 Jan; 47(1):319-22. doi:
NULL. [PMID: 3024818] - H F Newman, N M Bleehen, P Workman. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
International journal of radiation oncology, biology, physics.
1986 Jul; 12(7):1113-6. doi:
10.1016/0360-3016(86)90238-5. [PMID: 2943709] - C N Coleman, T H Wasserman, R C Urtasun, J Halsey, V K Hirst, S Hancock, T L Phillips. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
International journal of radiation oncology, biology, physics.
1986 Jul; 12(7):1105-8. doi:
10.1016/0360-3016(86)90236-1. [PMID: 3017904] - J M Brown. Sensitizers and protectors in radiotherapy.
Cancer.
1985 May; 55(9 Suppl):2222-8. doi:
10.1002/1097-0142(19850501)55:9+<2222::aid-cncr2820551426>3.0.co;2-k. [PMID: 2983876] - C N Coleman. Hypoxic cell radiosensitizers: expectations and progress in drug development.
International journal of radiation oncology, biology, physics.
1985 Feb; 11(2):323-9. doi:
10.1016/0360-3016(85)90154-3. [PMID: 3156109] - D G Hirst, M R Horsman, J M Brown, J L Hazlehurst. The effect of timing on chemosensitization by clinical levels of SR-2508.
International journal of radiation oncology, biology, physics.
1984 Sep; 10(9):1641-5. doi:
10.1016/0360-3016(84)90519-4. [PMID: 6237082] - C N Coleman, R C Urtasun, T H Wasserman, S Hancock, J W Harris, J Halsey, V K Hirst. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
International journal of radiation oncology, biology, physics.
1984 Sep; 10(9):1749-53. doi:
10.1016/0360-3016(84)90542-x. [PMID: 6237086] - P J Eifel, J M Brown. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
International journal of radiation oncology, biology, physics.
1984 Aug; 10(8):1311-4. doi:
10.1016/0360-3016(84)90338-9. [PMID: 6236186] - C N Coleman, W W Lee, L S Constine, J M Brown. The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508.
International journal of radiation oncology, biology, physics.
1982 Mar; 8(3-4):431-4. doi:
10.1016/0360-3016(82)90654-x. [PMID: 6213588] - J M Brown, N Y Yu, D M Brown, W W Lee. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.
International journal of radiation oncology, biology, physics.
1981 Jun; 7(6):695-703. doi:
10.1016/0360-3016(81)90460-0. [PMID: 6457018]